Phase I Evaluation of MEDI5752 Combined with Stereotactic Radiotherapy in Metastatic Soft Tissue Sarcoma Patients

The primary objective of this Phase I study is to evaluate the **safety** and **efficacy** of MEDI5752 in combination with stereotactic radiotherapy in patients with **metastatic soft tissue sarcoma**. This is clinically relevant as metastatic soft tissue sarcoma is a challenging condition with limited treatment options, and the combination of MEDI5752 with radiotherapy may offer a novel therapeutic approach. The study aims to determine the potential benefits and risks associated with this combination therapy, which could inform future treatment strategies for this patient population.

The clinical trial focuses on individuals diagnosed with **metastatic soft tissue sarcoma**. The study population includes both male and female participants, encompassing an age range that includes both adults and older adults. The trial involves a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Participants were selected based on criteria that are not disclosed in the available data. Lifestyle considerations such as diet, physical activity, or habits are not specified. The sponsor has not provided information on key inclusion or exclusion criteria for this trial.

The clinical trial is designed to evaluate the safety and efficacy of **MEDI5752** in combination with stereotactic radiotherapy in patients diagnosed with **metastatic soft tissue sarcoma**. This study is structured as a Phase I trial, which is typically the initial phase in clinical research aimed at assessing the safety profile of a new treatment. The trial will employ a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated duration of the trial spans from the recruitment start date on December 12, 2023, to the anticipated end date on June 12, 2028.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. This initial visit is crucial for determining eligibility based on predefined criteria. Following successful inclusion, participants will attend regular follow-up visits, which are essential for monitoring the treatment's effects and any adverse reactions. The sequence of these visits is designed to gather comprehensive data on the treatment's impact over time. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the intervention.

The expected length of participant involvement in the study is approximately four and a half years, aligning with the overall trial duration. However, certain conditions may necessitate early termination from the study. These conditions include, but are not limited to, the occurrence of severe adverse events, withdrawal of consent by the participant, or any other medical or ethical reasons deemed significant by the study investigators. The trial's methodology and design are meticulously crafted to ensure the collection of robust and reliable data, contributing to the advancement of treatment options for **metastatic soft tissue sarcoma**.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific information, additional relevant details about drug administration, dosing schedules, and participant compliance monitoring are also not included. The absence of data on the **experimental medication** and non-experimental treatments limits the ability to provide a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on December 12, 2023, with an estimated completion date of June 12, 2028. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for these assessments, are not specified in the provided information. The trial's focus on efficacy is aligned with the objectives typical of a Phase 3 study, which generally aims to confirm the effectiveness of a treatment in a larger patient population. The trial's design and execution will adhere to rigorous standards to ensure the reliability and validity of the efficacy data collected.